BR0207704A - Alfa interferon modificado com imunogenicidade reduzida - Google Patents

Alfa interferon modificado com imunogenicidade reduzida

Info

Publication number
BR0207704A
BR0207704A BR0207704-3A BR0207704A BR0207704A BR 0207704 A BR0207704 A BR 0207704A BR 0207704 A BR0207704 A BR 0207704A BR 0207704 A BR0207704 A BR 0207704A
Authority
BR
Brazil
Prior art keywords
alpha interferon
reduced immunogenicity
polypeptides
modified
modified alpha
Prior art date
Application number
BR0207704-3A
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Tim Jones
Matthew Baker
John Watkins
Marian Hanlon
Original Assignee
Merck Patent Ges Mit Beschaenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschaenk filed Critical Merck Patent Ges Mit Beschaenk
Publication of BR0207704A publication Critical patent/BR0207704A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ALFA INTERFERON MODIFICADO COM IMUNOGENICIDADE REDUZIDA". A presente invenção refere-se a polipeptídeos a serem administrados especialmente a seres humanos e em particular para uso terapêutico. Os polipeptídeos são polipeptídeos modificados em que a modificação resulta em uma propensão reduzida para que o polipeptídeo estimule uma resposta imune quando de administração ao ser humano. A invenção refere-se, em particular, à modificação de alfa interferon humano e especificamente alfa interferon 2 humano (INF<244>2) para resultar em proteínas que são substancialmente não imunogênicas ou menos imunogênicas do que qualquer contra-parte não-modificada quando usadas in vivo.
BR0207704-3A 2001-03-02 2002-03-01 Alfa interferon modificado com imunogenicidade reduzida BR0207704A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105088 2001-03-02
PCT/EP2002/002218 WO2002085941A2 (en) 2001-03-02 2002-03-01 Modified interferon alpha with reduced immunogenicity

Publications (1)

Publication Number Publication Date
BR0207704A true BR0207704A (pt) 2004-07-06

Family

ID=8176646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207704-3A BR0207704A (pt) 2001-03-02 2002-03-01 Alfa interferon modificado com imunogenicidade reduzida

Country Status (13)

Country Link
US (1) US20060062761A1 (pt)
EP (1) EP1379555A2 (pt)
JP (1) JP2004535173A (pt)
KR (1) KR20030081479A (pt)
CN (1) CN1529714A (pt)
BR (1) BR0207704A (pt)
CA (1) CA2439690A1 (pt)
HU (1) HUP0303309A2 (pt)
MX (1) MXPA03007838A (pt)
PL (1) PL363181A1 (pt)
RU (1) RU2003129056A (pt)
WO (1) WO2002085941A2 (pt)
ZA (1) ZA200307677B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
MXPA05008704A (es) * 2003-02-18 2005-10-05 Merck Patent Gmbh Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US20110224407A1 (en) * 2008-09-09 2011-09-15 University Of Medicine And Dentistry Of New Jersey Type I Interferon Antagonists
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
CN105255840A (zh) * 2015-10-16 2016-01-20 西安医学院 通过去除显性表位b8r重组痘苗病毒的方法及其病毒
CN105200017A (zh) * 2015-10-16 2015-12-30 西安医学院 一种去除a47l降低痘苗病毒免疫优势的方法及病毒
AU2018258061A1 (en) 2017-04-28 2019-11-28 National Jewish Health Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene
AR117715A1 (es) * 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
JP2024517475A (ja) * 2021-05-10 2024-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 自己免疫を治療するための操作されたｈｌａ対立遺伝子

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728146B2 (en) * 1996-03-14 2001-01-04 Immune Response Corporation, The Targeted delivery of genes encoding interferon

Also Published As

Publication number Publication date
WO2002085941A2 (en) 2002-10-31
RU2003129056A (ru) 2005-04-20
PL363181A1 (en) 2004-11-15
US20060062761A1 (en) 2006-03-23
KR20030081479A (ko) 2003-10-17
WO2002085941A3 (en) 2003-10-30
CA2439690A1 (en) 2002-10-31
EP1379555A2 (en) 2004-01-14
HUP0303309A2 (hu) 2003-12-29
JP2004535173A (ja) 2004-11-25
ZA200307677B (en) 2004-07-13
CN1529714A (zh) 2004-09-15
MXPA03007838A (es) 2003-12-08

Similar Documents

Publication Publication Date Title
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
BR0207016A (pt) Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
BR0308860A (pt) Fator viii modificado
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
BR0207705A (pt) Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida
BR0207945A (pt) Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade
BR0211091A (pt) Métodos para redução de imunogenicidade de polipeptìdeos
BR0207542A (pt) Trombopoietina modificada com imunogenicidade reduzida
BR0207017A (pt) Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida
BR0207020A (pt) Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida
BR0208120A (pt) Insulina modificada com imunogenicidade reduzida
BR0211991A (pt) HormÈnio do crescimento humano modificado
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
BR0213554A (pt) Timosina para aumento da imunização genética
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.